Trials / Unknown
UnknownNCT05875558
M-TACE Treatment for Unresectable Hepatocellular Carcinoma
Lipiodol Combined With Microspheres TACE for Unresectable HCC
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to investigate the safety and efficacy of transarterial chenmoembolization（TACE） combined with microspheres for unresectable hepatocellular carcinoma(HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | M-TACE | Lipiodol combined with microspheres |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2023-12-01
- Completion
- 2024-07-01
- First posted
- 2023-05-25
- Last updated
- 2023-05-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05875558. Inclusion in this directory is not an endorsement.